These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19908230)

  • 1. The effects of telomerase inhibition on prostate tumor-initiating cells.
    Marian CO; Wright WE; Shay JW
    Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?
    Marian CO; Shay JW
    Biochim Biophys Acta; 2009 Apr; 1792(4):289-96. PubMed ID: 19264126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
    Chen Z; Koeneman KS; Corey DR
    Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
    Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
    Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology.
    Meeker AK
    Urol Oncol; 2006; 24(2):122-30. PubMed ID: 16520276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
    Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
    Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells.
    Verma V; Sharma V; Singh V; Sharma S; Bishnoi AK; Chandra V; Maikhuri JP; Dwivedi A; Kumar A; Gupta G
    Toxicol Appl Pharmacol; 2014 Oct; 280(2):323-34. PubMed ID: 25123791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
    Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS
    Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
    Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
    J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines.
    Adler S; Rashid G; Klein A
    Anticancer Res; 2011 Nov; 31(11):3733-7. PubMed ID: 22110194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere length and telomerase activity in bladder and prostate cancer cell lines.
    Kageyama Y; Kamata S; Yonese J; Oshima H
    Int J Urol; 1997 Jul; 4(4):407-10. PubMed ID: 9256332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.